Is Oscar Health (OSCR) Still Below Fair Value After 3.6x Gains?

Oscar Health stock has delivered very strong 3 year gains, yet the broad valuation checks currently lean expensive and do not clearly support it as a bargain. After such a sharp move, investors are trying to work out whether the recent share price now runs ahead of the fundamentals or is still justified by the company’s prospects.

• Oscar Health has returned about 3.6x over 3 years, which puts extra focus on whether recent gains already reflect much of the potential that investors see in the business.

• Expectations that Oscar Health can improve profitability and cash flow from its health insurance model may support the current share price, while execution risk on costs and underwriting performance remains a key threat to that valuation case.

• The broader checks flag Oscar Health as 2 of 6 on the value score, which means the stock leans expensive rather than showing up as a clear bargain on this framework.

The issue now is whether Oscar Health’s current price leaves enough room for investors who are considering the stock after its very strong 3 year run.

Compare Oscar Health’s sharp multi year move with other stocks that have strong fundamentals screened for you in the 44 high quality undervalued stocks.

Does Oscar Health Look Undervalued on Earnings?

The P/E ratio is a useful cross check here because Oscar Health has positive earnings to anchor the comparison. Oscar Health currently trades on a P/E of 17.1x. That is higher than the Insurance industry average of 11.3x, yet it is well below the peer group average of 36.1x, so the stock does not screen as stretched versus similar companies that investors often compare it with.

A more tailored yardstick is the Fair P/E ratio of 24.8x, which reflects what might be expected for Oscar Health given its sector, size and risk profile. Against that yardstick, the current 17.1x represents a sizeable discount, even after the strong share price move. For readers, the key question is whether the business can sustain the earnings that underpin this multiple.

On this P/E check, Oscar Health stock appears undervalued relative to the level implied by this framework.

See what the numbers say about this price — find out in our valuation breakdown.

The Oscar Health Narrative: What Would Justify Today’s Price?

Simply Wall St Narratives for Oscar Health pick up where the valuation checks leave off and explain which future paths for growth, margins and earnings would need to hold for the stock to be worth materially more or less than today’s price. Each Narrative links a specific fair value estimate to a clear story about Oscar Health’s possible catalysts and risks, so you can track over time which version of events appears to be taking shape on the Community page.

Community views on Oscar Health are sharply split, with one camp seeing deep value and the other flagging meaningful downside risk.

Bull case: 95% undervalued

“The market is mispricing this asset by an order of magnitude…”

Read the full Bull Case to see why Oscar Health could be undervalued

Bear case: 26% overvalued

“Higher claims costs and evolving policy risks threaten profitability and future membership growth, despite efforts to reprice plans and leverage digital adoption trends…”

Read the full Bear Case to see why Oscar Health could be overvalued

Do you think there’s more to the story for Oscar Health? Head over to our Community to see what others are saying!

The Bottom Line

Oscar Health screens as somewhat undervalued on earnings based on its current P/E against the tailored fair multiple, yet the broader checks are not especially supportive and point to a weaker overall value case. That split reflects a market that already prices in a fair amount of optimism, while still leaving some room if the company can deliver on its profitability goals. The key question for investors is whether Oscar Health can improve margins and underwriting quality enough to justify its current earnings multiple, rather than leaving the apparent discount as a value trap tied to execution risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include OSCR.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com